The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting cancer with small-molecule pan-KRAS degraders
Open accessPublished version of a preprint
Abstract
Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PROTAC (proteolysis-targeting chimera) technologies are designed to induce selective degradation of KRAS proteins through recruitment of E3 ubiquitin ligases and subsequent proteasomal destruction [61,62,63,64].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [62]
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
UCSF ChimeraX: Structure visualization for researchers, educators, and developers
Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., Morris, J. H., & Ferrin, T. E. (2021) · Protein Science · doi:10.1002/pro.3943 · Cited by 9,514
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Cited by
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“Pan-KRAS PROTAC degraders have also been described, such as ACBI3, which degrades all KRAS mutants; however, activity has yet to be reported in vivo and these compounds have not entered clinical development 80 .”
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 210
Self-citationKRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 118
Discovery of KRAS(G12D) selective degrader ASP3082
Yoshinari, T., Nagashima, T., Ishioka, H., Inamura, K., Nishizono, Y., Tasaki, M., Iguchi, K., Suzuki, A., Sato, C., Nakayama, A., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01662-4 · Cited by 87
“Recently, a pan-KRAS degrader, ACBI3, that contains a triazole ring in the VHL ligand has been reported 35 , and similar to our fi ndings, the triazole group in the VHL ligand of ACBI3 strongly interacts with VHL.”
Targeting KRAS: from metabolic regulation to cancer treatment
Shi, Y., Zheng, H., Wang, T., Zhou, S., Zhao, S., Li, M., & Cao, B. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02216-3 · Cited by 89
“A new PROTAC drug has been reported to degrade 13 out of 17 of the most common oncogenic KRAS mutations [180].”
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 82
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“Similarly, ACBI3 is a pan-KRAS PROTAC degrader active against 13 of 17 of the most common KRAS mutations; it demonstrated potent and durable inhibition of KRAS signaling in vitro and tumor regression in vivo (157).”
Confounding Factors in Targeted Degradation of Short-Lived Proteins
Vetma, V., Perez, L. C., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00152 · Cited by 54
Self-citationDevelopment of PROTAC Degrader Drugs for Cancer
Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 65
Self-citationLessons learned in linking PROTACs from discovery to the clinic
Pike, A., Lee, E. C. Y., Michaelides, I. N., Schade, M., Sharma, A., Scott, J. S., & Srivastava, A. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00784-6 · Cited by 65
“Linked to cooperativity, the stability and longevity of the ternary complex has also been characterized to rationalize improvements in potency 45,50 , as described recently by Popow and coworkers following the structure-guided design of VHL-harnessing Kirsten rat sarcoma viral oncogene homologue…”
Feng, J., Xiao, X., Xia, X., Min, J., Tang, W., Shi, X., Xu, K., Zhou, G., Li, K., Shen, P., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.006 · Cited by 45
Liu, J., Ma, T., Yao, R., Li, L., Zheng, Q., & Wang, M. (2026) · Cell · doi:10.1016/j.cell.2025.12.007 · Cited by 33
Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
Lu, X., Wang, X., Liao, H., Sha, B., Zhang, Y., & Li, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510641 · Cited by 35
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Holmqvist, A., Kocatürk, N. M., Duncan, C., Riley, J., Baginski, S. R., Marsh, G. P., Cresser-Brown, J. O., Maple, H. J., Juvonen, K. R., Sathe, G. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63928-8 · Cited by 32
“…controlled removal of one or both isoforms and its impact on the activation status of different GSK3 substrates, as well as the potential to leverage pharmacokinetic/pharmacodynamic disconnects, characteristic of degraders 28 , which may differ in effect from occupancy-based inhibition in vivo.”
InfluentialSelf-citationOuyang, D., Yang, R., Yao, Y., Jiang, F., Song, S., Yang, Y., Ogunnaike, E. A., Chen, Z., Chen, Z., & Yang, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c15945 · Cited by 27
Kumar, H., & Sobhia, M. E. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00189 · Cited by 26
Accurate PROTAC-targeted degradation prediction with DegradeMaster
Liu, J., Roy, M. J., Isbel, L., & Li, F. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf191 · Cited by 34
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
“Recently, the Ciulli group developed the selective, potent, and in vivo active pan-KRAS degrader molecule ACBI3 [72] (Fig.”
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“Pan-KRAS inhibitors that are able to block all mutant proteins are necessary [145].”
Ma, N., Bhattacharya, S., Muk, S., Jandová, Z., Schmalhorst, P. S., Ghosh, S., Le, K., Diers, E., Trainor, N. B., Farnaby, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63713-7 · Cited by 28
“7.”
Self-citationPredicting PROTAC-mediated ternary complexes with AlphaFold3 and Boltz-1
Dunlop, N., Erazo, F., Jalalypour, F., & Mercado, R. (2025) · Digital Discovery · doi:10.1039/d5dd00300h · Cited by 32
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers
Jeong, J., Hausmann, S., Dong, H., Szczepski, K., Flores, N. M., Gonzalez, A. G., Shi, L., Lu, X., Lempiäinen, J. K., Jakab, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09299-y · Cited by 24
“Notably, the selective KRAS G12C inhibitors sotorasib (also known as AMG510) and adagrasib (also known as MRTX849) recently received approval by the US Food and Drug Administration for cancer treatment 31,32 , and several other RAS inhibitors are in development 33–35 .”
Badonyi, M., & Marsh, J. A. (2025) · Nature Communications · doi:10.1038/s41467-025-63234-3 · Cited by 19
“Diseases resulting from LOF mutations are usually amenable to gene therapy, where the deliveryof functional gene copies compensates for the defective allele.”
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics
Xu, M., & Xu, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02309-7 · Cited by 24
“In the GP2 d xenograft model, daily dosing at 30 mg/kg significantly reduced intratumoral KRASG12D levels to 44% of con-trol and achieved a remarkable 127% tumor growth inhibition over a 14-day period—leading to marked tumor regression without significant changes in body weight [539].”
The “three body solution”: Structural insights into molecular glues
Tomlinson, A. C. A., Knox, J. E., Brunsveld, L., Ottmann, C., & Yano, J. K. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103007 · Cited by 23
Xiao, Z., Gavriil, E.-S., Cao, F., Zhang, X., Li, S. X., Kotelnikov, S., Michalska, P., Marte, F., Huang, C., Lu, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01420 · Cited by 19
DNA methylation protects cancer cells against senescence
Chen, X., Yamaguchi, K., Rodgers, B., Goehrig, D., Vindrieux, D., Lahaye, X., Nolot, M., Ferry, L., Lanciano, S., Martin, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61157-7 · Cited by 17
“For instance, spurious intragenic transcriptionparticipates to senescence 82 , while the histone chaperone HIRA plays a histone-independent role in SASP induction 83 .”
Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy
Bröeker, J., Waterson, A. G., Hodges, T. R., Abbott, J. R., Arnold, A. L., Böttcher, J., Braun, N., Cui, J., Fuchs, J. E., Gerstberger, T., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00576 · Cited by 21
Qiu, Y., Wiewiora, R., Izaguirre, J. A., Xu, H., Sherman, W., Tang, W., & Huang, X. (2024) · JACS Au · doi:10.1021/jacsau.4c00503 · Cited by 20
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Li, D., Geng, K., Yuan, H., Gu, J., Kumar, S., Olson, A. T., Kuismi, C. C., Kim, H. M., Pan, Y., Sherman, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174249 · Cited by 21
“Furthermore, although pan-KRAS degraders are in preclinical development (23–25) and KRAS G12D degraders are in clinical trials (NCT05382559) (26), the consequences of targeted KRAS G12V degradation in immune-competent models and the characterization of KRAS G12V -selective degraders remain largely…”
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 19
Ma, J., Fu, S., Tan, J., Han, Y., Chen, Y., Deng, X., Shen, H., Zeng, S., Peng, Y., & Cai, C. (2025) · Advanced Science · doi:10.1002/advs.202502714 · Cited by 23
Structural basis for LZTR1 recognition of RAS GTPases for degradation
Dharmaiah, S., Bonsor, D. A., Mo, S., Fernandez-Cabrera, A., Chan, A. H., Messing, S., Drew, M. R., Vega, M., Nissley, D. V., Esposito, D., et al. (2025) · Science · doi:10.1126/science.adv7088 · Cited by 19
PRosettaC outperforms AlphaFold3 for modeling PROTAC ternary complexes
Schulz, J. M., Schürer, S. I., Reynolds, R. C., & Schürer, S. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-21502-8 · Cited by 16
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability
Wu, H., Murray, J. M., Ishisoko, N., Frommlet, A., Deshmukh, G. S., DiPasquale, A. G., Mulvihill, M. M., Zhang, D., Quinn, J. G., Blake, R. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02203 · Cited by 16
Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
Dominguez, A. A., Perz, M., Xu, Y., Cedillo, L. G., Huang, O. L., McIntyre, C. A., Vudatha, V., Trevino, J. G., Liu, J., & Wang, P. (2024) · Cancers · doi:10.3390/cancers16213564 · Cited by 17
Urbina, A., Hallatt, A. J., Robertson, J., & Ciulli, A. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446232 · Cited by 19
“Recent advances made with CryoEM to resolve ternary complex structures at increasingly higher resolution and to understand the mechanism of VHL mediated PROTAC degradation and ubiquitination could also allow for new insights into developing VHL-based degraders [111,112].”
Self-citationIdentification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 20
“33 However, four alleles were not effectively degraded by ACBI3, namely, G12R, Q61K, Q61L, and Q61R.”
InfluentialSelf-citationBreaking down KRAS: Small-molecule degraders for cancer therapy
Kos, T., & Saur, D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02172-4 · Cited by 15
ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer
Liu, Z., Zheng, H., Tian, Y., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01034 · Cited by 14
Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research
Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025) · Small Methods · doi:10.1002/smtd.202500402 · Cited by 13
Rational modification of PROTACs for tumor-selective protein degradation
Fu, Z., Pan, M., Yang, C., Hou, H., & Li, J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115775 · Cited by 15
G protein-coupled receptor–targeted proteolysis-targeting chimeras in cancer therapeutics
Saca, V. R., Huber, T., & Sakmar, T. P. (2024) · Molecular Pharmacology · doi:10.1016/j.molpha.2024.100013 · Cited by 11
DeCorte, J. A., Brown, B. P., Jeffrey, R., & Meiler, J. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01472 · Cited by 13
Nondegradative Synthetic Molecular Glues Enter the Clinic
Repity, M. L., Deutscher, R. C. E., & Hausch, F. (2025) · ChemMedChem · doi:10.1002/cmdc.202500048 · Cited by 12
KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants
Jeon, E., Kim, C., Ko, M., Kim, T. K., Bae, J., Oh, J. W., Kim, K. P., Kim, H. S., & Sim, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117928 · Cited by 10
Vascular malformations: from genetics to therapeutics
Morin, G., Galasso, I., & Canaud, G. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00344-x · Cited by 10
“RAS-targeted PROTACs are also underway, with ACBI3 degrading most of the common KRAS mutants and inducing tumor regression in vivo (Popow et al, 2024).”
KRAS takes the road to destruction
Cox, A. D., & Der, C. J. (2024) · Science · doi:10.1126/science.ads2150 · Cited by 9
Qu, X., Jiang, C., Shan, M., Ke, W., Chen, J., Zhao, Q., Hu, Y., Liu, J., Qin, L., & Cheng, G. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01732 · Cited by 9
Leini, R., Kapp, J. N., Kopra, K., & Pantsar, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-07532-2 · Cited by 9
“Furthermore, Boehringer-Ingelheim in collaboration with the Ciulli Laboratory reported SII-P utilizing pan-RAS degraders 35 ; they published the co-crystal structure of the lead compound used to guide the linker design (8QUG) along with three ternary complexes of the degraders (8QW6; 8QW7; 8QVU).”
Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors
El-Ghazzi, N., Italiano, A., & Angeli, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657040 · Cited by 10
“Different inhibitory strategies are currently under investigation, including inhibition at a common site of KRAS protein (pan-KRAS inhibitors) (89), or molecular glues — an emerging approach that promotes the binding of KRAS to a degradation enzyme (90).”
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 9
“…for KRAS: ASP3082 (a KRASG12D degrader) shows acceptable safety and early activity, while the pan-KRAS https://doi.org/10.3390/jcm15020873 PROTAC ACBI3 degrades multiple KRAS mutants, illustrating catalytic elimination as a modality to overcome scaffolding and residual signaling [64,179,180].”
InfluentialProteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adt6552 · Cited by 8
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 8
“179 Their large size also limits oral absorption and tumor penetration.”
Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 8
“Pan-RAS or mutation-agnostic inhibitors, as well as RAS degraders, are also being explored as broader strategies, but none have yet received clinical approval [5, 13–16].”
Inhibition of GTPase KRAS G12D : a review of patent literature
Li, Y., Yang, L., Li, X., & Zhang, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2369630 · Cited by 9
“Researchers developed a class of pan-KRAS degraders through modification of the VHL ligand and connection from the N -4 site [95].”
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Piech, S., Brüschweiler, S., Westphalen, J., Siess, K. M., Murias, J. G., Konrat, R., Bigenzahn, J. W., & Superti‐Furga, G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00077 · Cited by 7
Drugging Challenging Cancer Targets Using Fragment-Based Methods
Fesik, S. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00892 · Cited by 9
Zhou, C., Liu, Y., Liu, H., Lü, J., Zhang, B., Zhu, L., Wang, S., Lei, H.-M., & Han, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07992-4 · Cited by 6
“In addition to the increasing number of KRAS G12C inhibitors, G12D inhibitors [47, 48] and pan-KRAS inhibitors [49, 50] are also under development or entering clinical trials.”
Molecular glues: A new path to the world of the unattainable
Khaledian, M., Sheikh, H., Babaei, F., Divsalar, A., Gharshasbi, M., Ottmann, C., Haertlé, T., Saboury, A. A., & Rasouli, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148861 · Cited by 8
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6
Self-citationLinkerology in PROTACs: learnings for proximity-inducing therapeutics
Prieto‐Díaz, R., Urbina, A., Rodriguez-Rios, M., & Ciulli, A. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.07.004 · Cited by 7
Self-citationLi, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
An overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Han, Z., Wu, Q., Rao, H., Xu, T., & Zhou, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130283 · Cited by 5
Escher, T. E., Yuk, S. A., Yuan, Q., Qiang, W., Almunif, S., Sharma, S., Scott, E. A., & Satchell, K. J. F. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00179 · Cited by 4
Proteostasis of immune checkpoint receptors
Tey, P. Y., Urbé, S., & Clague, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20253299 · Cited by 4
“…of this class, termed proteolysis targeting chimaeras (PROTACs), was originally proven effective at targeting membrane receptors (e.g. RTKs), and the approach has now been extended to degrading scaffold proteins and oncogenic enzymes that are otherwise hard to target by inhibitors alone [255–258].”
Raines, B., Tseng-Rogenski, S. S., Dowdican, A. C., Peris, I., Hinderman, M., Zawacki, K. P., Barrie, K., Onishi, G. H., Dymond, A. M., Luther, T. K., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci193790 · Cited by 5
“Recently, K-Ras degraders have offered a promising approach by eliminating the protein, but they remain clinically unproven and may face limited efficacy due to resistance mechanisms like target mutations, E3 ligase alterations, or pathway rewiring that reduces K-Ras dependency (50–53).”
Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer
Lin, L., Zheng, F., Wei, H., Wu, X., Yan, H., & Ding, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118432 · Cited by 5
Targeted protein degradation: species, diseases and efficient utilization
Yue, T., He, J., & Hou, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07610-z · Cited by 5
“…however, due to the discovery of KRAS binding site in the previous studies and the successful degradation of PROTACs (named ACBI3) developed by utilizing VHL as a ubiquitin ligase to degrade KRAS, the researchers found that ACB13 was still effective in targeting mutant proteins of KRAS [53].”
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 12
Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
Lu, X., Wang, X., Liao, H., Sha, B., Zhang, Y., & Li, J. (2025) · Angewandte Chemie · doi:10.1002/ange.202510641 · Cited by 7
Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells
Zheng, Q., Shen, T., Pampel, J., & Shokat, K. M. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00249 · Cited by 4
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCPreprint
Alonso, S., Chu, K., Parsons, M. J., Granowsky, E., Gunasinghe, H. I., Shia, J., Yaeger, R. D., & Dow, L. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.05.668666 · Cited by 4
Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Yu, Z., Wu, C., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.031 · Cited by 7
“Using this technique, Popow et al. 30 developed von Hippel-Lindau (VHL)- based PROTACs to target various oncogenic K-RAS mutants for degradation.”
Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers
Jiang, L., Chen, Y., Zhao, J., Zhou, L., Zhou, Q., Jiang, H., Lou, D., Huang, W., & Zhang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109161 · Cited by 6
Wang, Y., & Peng, J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108054 · Cited by 3
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 4
Kumar, H., & Sobhia, M. E. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07053 · Cited by 5
Discovery of KRAS-G12D degraders via exploration of various E3 ligases
Yim, H., Song, X., Zhong, Y., Hu, J., Xiong, Y., & Jin, J. J. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118635 · Cited by 3
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Development of PROTACs for targeted degradation of oncogenic TRK fusions
Kumar, S., Jiang, J., Donald-Paladino, M. S., Chen, J., Gutierrez, A., Alexander Joel Federation, Szulzewsky, F., Holland, E. C., Ferguson, F. M., & Nabet, B. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00008h · Cited by 4
Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations
Deng, J., Shen, S., Huang, L., Xu, F., Huang, W., Huang, C., Zhang, Z., Liu, T., Tan, Y., & Li, Z. (2026) · Nature Communications · doi:10.1038/s41467-026-71093-9 · Cited by 4
“Targeted protein degradation (TPD) harnesses the cell ’ s endogenous proteolytic machinery to selectively eliminate proteins of interest 23,24 .”
Advantages of PROTACs in achieving selective degradation of homologous protein families
Yang, L., Mao, X., Zhang, J., Shu, J., Huang, W., Dong, X., Chen, Y., & Wu, M. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.49 · Cited by 3
García-Bautista, A., Cenigaonandia‐Campillo, A., Río-Vilariño, A., Sanz-Criado, L., Selva‐Gimenez, M., Antolín, R. P., Cebrián, A., García‐García, L., Fernández-Aceñero, M. J., Baños‐Herraiz, N., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101314 · Cited by 4
“Despite recent advances, including the development of mutant-selective KRAS inhibitors [4,5] and KRAS-directed degraders [6], clinical efficacy is frequently compromised by intrinsic and adaptive resistance mechanisms.”
Linker-Driven Sampling of PROTAC-Induced Ternary Complexes
Zhao, H., Schießer, S., Tyrchan, C., & Czechtizky, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00527 · Cited by 7
D'Alessio‐Sands, L., Gaynier, J., Michel‐Milian, V., Agbowuro, A. A., & Brackett, C. M. (2025) · Drug Development Research · doi:10.1002/ddr.70042 · Cited by 6
“At a S.C. daily dose of 30 mg/kg for 14 days, ACBI3 produced tumor regressions of − 127% ( p < 0.0001) with no significant impact on body weight, suggesting good systemic tolerance in the mice (Popow et al. 2023).”
InfluentialGene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Zou, J. P., Han, W., Hu, Y. T., Zeng, C., Li, J., Lei, W., Cao, J., Fei, Q., Shao, M., Yi, J., et al. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03680-x · Cited by 4
Recent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 7
Efficient Sampling of PROTAC-Induced Ternary ComplexesPreprint
Zhao, H., Schießer, S., Tyrchan, C., & Czechtizky, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.30.619573 · Cited by 3
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges
Yang, X., Li, X., Zhang, Y., Zhang, S., Zhang, M., Sun, C., Yang, L., Liu, H., & Yuan, S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2444865 · Cited by 3
Mair, T., König, P., Mijović, M., Kalla, J., Baskan, A., Tran, L., Draganić, K., Saldaña, P. M., Malla, C. U. P., Pfneissl, J., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70014 · Cited by 2
“To test whether the insensitivity of PDT1 towards TGF-b 1 was dependent on KRAS signaling, we used the panKRAS inhibitor BI-2865 [43] and the KRAS degrader ACBI3 [44], which both showed high efficacy against PDT1 (Fig.”
Loveček, M., Strouhal, O., Červenková, L., Šůsová, S., Hlaváč, V., Dvorakova, M. C., Holý, P., Liška, V., Skalický, P., Škanderová, D., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104205 · Cited by 2
Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system
Teng, F., Gao, Q., Li, Z., Cui, T., Tan, X., Ding, Y., Li, R., Li, B., Zhong, B., Miao, M., et al. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.031 · Cited by 2
Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches
Karki, R., Chen, R., & Pan, S. (2025) · Current Oncology · doi:10.3390/curroncol32110614 · Cited by 3
“Cryo-EM structure studies and whole-cell proteomic studies indicated that ACBI3 assumes a fishhook structure and engages the VHL E3 ligase with KRAS for ubiquitination, and the KRAS protein is selectively degraded, sparing HRAS and NRAS [108].”
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 5
Metadata
- Authors
- Popow, J., Farnaby, W., Gollner, A., Kofink, C., Fischer, G., Wurm, M., Zollman, D., Wijaya, A., Mischerikow, N., Hasenoehrl, C., Prokofeva, P., Arnhof, H., Arce-Solano, S., Bell, S., Boeck, G., Diers, E., Frost, A. B., Goodwin-Tindall, J., Karolyi-Oezguer, J., Khan, S., Klawatsch, T., Koegl, M., Kousek, R., Kratochvil, B., Kropatsch, K., Lauber, A. A., McLennan, R., Olt, S., Peter, D., Petermann, O., Roessler, V., Stolt-Bergner, P., Strack, P., Strauss, E., Trainor, N., Vetma, V., Whitworth, C., Zhong, S., Quant, J., Weinstabl, H., Kuster, B., Ettmayer, P., & Ciulli, A.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- University of Dundee (GB)
- Technical University of Munich (DE)
- Boehringer Ingelheim (United States) (US)
- Division of Biological Chemistry and Drug Discovery, School of Life Sciences, James Black Centre, University of Dundee, Dundee DD1 5EH, UK.
- Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria.
- Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, 85354 Freising, Germany.
- Corresponding author
- Ciulli, Alessio
- ORCID
- Popow, Johannes
- Farnaby, William
- Gollner, Andreas
- Kofink, Christiane
- Fischer, Gerhard
- Wurm, Melanie
- Zollman, David
- Wijaya, Andre
- Prokofeva, Polina
- Arce-Solano, Silvia
- Bell, Sammy
- Boeck, Georg
- Diers, Emelyne
- Frost, Aileen B.
- Klawatsch, Theresa
- Koegl, Manfred
- Lauber, Arnel A.
- McLennan, Ross
- Peter, Daniel
- Stolt-Bergner, Peggy
- Trainor, Nicole
- Vetma, Vesna
- Whitworth, Claire
- Zhong, Siying
- Quant, Jens
- Weinstabl, Harald
- Kuster, Bernhard
- Ettmayer, Peter
- Ciulli, Alessio
- Venue
- Science
- Published
- 2024-09-20
- Volume
- 385
- Issue
- 6715
- Pages
- 1338-1347
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4402625837
- Semantic Scholar
- ed61350af26b096749adcb45351f0e69feb359f3
- Cited by
- 198
- References
- 50
- Citations by year
- 2026: 78 · 2025: 94 · 2024: 26
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Funders
- University of Dundee
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 097945/C/11/Z, 097945, 100476/Z/12/Z)
- Diamond Light Source (MX14980)
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS, oncogenic KRAS mutations, small-molecule degraders, heterobifunctional molecules, protein degradation, KRAS G12C, covalent inhibitors, ternary complex, KRAS-driven cancers, tumor regression
- MeSH terms
- Proteolysis Targeting Chimera, Alleles, Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Mice, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.